Abstract: An ascorbic acid-based composition and related method for the treatment of aging or photo-damaged skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid and may advantageously be formulated to have a pH above 3.5. Generally, the composition also includes non-toxic zinc salt, tyrosine compound, and/or pharmaceutically acceptable carrier. In addition, the composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. The topical composition may be in the form of a serum, a hydrophilic lotion, an ointment, a cream, or a gel.

Abstract: Water-circulating systems are treated with an aqueous, alkaline composition comprising I) an organo-phosphorus chelating agent, II) an acrylate homopolymer, III) a salt of an acrylic copolymer, a portion of the repeating units of which contain sulfonate groups, IV) a molybdate salt, and V) a salt of a fused-ring aromatic triazole. This composition (which is formulated in accordance with a specific order of addition of the ingredients) is effective against white rust (corrosion of galvanized metal parts). When the water-circulating system is also fouled with a biofilm, it is preferred to introduce a biofilm remover having biocidal, surfactant, and chelating properties into the system, but the biofilm remover is introduced separately from the above-described composition.

Abstract: Composition in the form of an aqueous solution, useful for disinfecting hard surfaces comprises: a) from 0.0005% to 20% by weight of peracetic acid, b) from 0.001% to 45% by weight of acetic acid, c) from 0.001% to 35% by weight of hydrogen peroxide, d) from 0.0001% to 2% by weight of at least one compound of formula (I) (R1) (R2) (R3)N→O  (I) e) if desired, up to 2.5% by weight of at least one nonionic surfactant, and wherein f) the weight ratio between the compound of formula (I) and the peracetic acid is less than or equal to 1, and in that g) the weight ratio between the nonionic surfactant and the peracetic acid is less than or equal to 0.2.

Abstract: A method of using a compound of formula (I) wherein R.sup.1, R.sup.2, R.sup.3, X and n have any of the meanings defined in the specification, to antagonize glutamate binding, or to treat glutamate-related disorders is provided. Novel compounds, intermediates and pharmaceutical compositions are also provided.

Abstract: NO precursors are administered at elevated levels in addition to the diet of the individual to enhance exercise performance. Particularly, L-arginine and L-lysine by enhancing endothelial NO production can provide for greater aerobic capacity and improved exercise performance.

Abstract: This invention provides a dietary supplement comprising L-Carnitine (or its functional analogues such as Acetyl-Carnitine or Proprionyl-l-Carnitine), Coenzyme Q10 and Taurine for the correction of the abnormality in mitochondrial energetics in cardiac failure and certain other diseases. A high protein nutritional feeding supplementation with Cysteine, Creatine, Vitamin E (RRR-d-alpha-tocopherol), Vitamin C (ascorbic acid), Selenium, and Thiamin in may be added.

Abstract: [Object] : To provide a pharmaceutical preparation for treating or preventing hyperlipemia which lowers cholesterols and neutral fats in blood and has a property to improve lipoprotein metabolism.[Construction] : A pharmaceutical preparation for treating or preventing hyperlipemia comprising taurine and .gamma.-oryzanol as effective components.

Abstract: Amide derivatives and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.

Abstract: The present invention relates to a new use of N,S-diacetylcysteine ethyl ester for the preparation of a pharmaceutical composition for treating virus-induced disease. In particular, the invention concerns the use of DACEE for the preparation of a pharmaceutical composition for treating virus-induced disease, the DACEE used destroying disulfide bridges present in viral proteins.

Abstract: Use of at least one aminothiol ester derivative for the preparation of a pharmaceutical composition intended to increase the inhibition of a character resistant to the induction of apoptosis of transformed cells, this character being due to the bc12 gene present in these cells. The pharmaceutical composition is more particularly intended to treat pathologies chosen from breast cancers, B cell lymphomas, leukaemias, neuroblastomas, adenocarcinomas of the prostate, prolactinomas and other pituitary adenomas.

Abstract: The invention relates to methods for inducing analgesia (or even anesthesia) and for prevention or amelioration of damage caused by ischemic or traumatic injury of tissues in general, but especially neural, for the central nervous system being the most vulnerable of all tissues, by the systemic administration of a therapeutically effective amount of primarily taurine, and secondarily homotaurine and/or methionine for a sufficient period of time (several hours to a few days, depending on the severity of the injury, and timing when therapy is initiated from the time of injury) to allow recovery from the original insult or from phenomena that follow the initial injury.

Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.

Abstract: Mammalian hair growth is reduced by inhibiting the activity of a matrix metalloproteinase in the skin.

Abstract: This invention is directed to a pharmacologically acceptable composition for inhibiting nitric oxide synthase in a mammal, which includes a mercapto derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting nitric oxide synthase, selectively inhibiting the inducible isoform of nitric oxide synthase, and treating various conditions where there is an advantage in inhibiting nitric oxide biosynthesis. The method includes the step of administering to a mammal a mercapto derivative in pure form or in a pharmaceutically acceptable carrier.

Abstract: Disclosed is a method for treating a hyperkinetic movement disorder comprising the steps of selecting a first at least one pharmacologically active agent that acts as a GABA-receptor agonist and a second at least one pharmacologically active agent that acts as a NMDA-type glutamate receptor antagonist, and administering the first and second agents at effective and non-toxic dosages.

Abstract: .alpha.-alkoxy and .alpha.-thioalkoxyamide compositions and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.

Abstract: Mammalian hair growth is reduced by applying an inhibitor of aminoacyl-tRNA synthetase to the skin.

Abstract: The present invention relates to methods of stimulating he growth of hematopoietic progenitor cells. In particular, it relates to the use of thiols and related compounds in stimulating the growth of hematopoietic progenitor cells in vitro and in vivo. Furthermore, the present invention relates to methods of using these compounds for the treatment of marrow failure states and immunodeficient conditions, including but not limited to myelodysplastic syndromes and acquired immunodeficiency syndrome.

Abstract: A method and pharmaceutical for protecting against mutational damage in mammalian cells, irrespective of the nature of the mutagenic event or source of radiational or chemical insult or the like.

Abstract: The present invention relates to methods of stimulating the growth of hematopoietic progenitor cells. In particular, it relates to the use of thiols and related compounds in stimulating the growth of hematopoietic progenitor cells in vitro and in vivo. Furthermore, the present invention relates to methods of using these compounds for the treatment of marrow failure states and immunodeficient conditions, including but not limited to myelodysplastic syndromes and acquired immunodeficiency syndrome.

Abstract: Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF.alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.

Abstract: The invention discloses a bait for fishes and shellfishes characterized in that the bait comprises a matrix material containing a microorganically fermented product of a plant residue obtained by separating from a plant at least one liquid selected from the group consisting of vegetable juice, fruit juice, plant essential oil, juice extracted from a processed plant product, plant milk and mixtures thereof, or disintegrated product of said microorganically fermented product, wherein the matrix material has incorporated therein (A) an amino acid having 2 or 3 carbon atoms, and (B) amino acid having at least 4 carbon atoms in an (A)/(B) molar ratio of 1:1 to 40:1.

Abstract: Dietary supplement formulation which increases lean body mass without concomitant increase of body fat mass, an effect parallel to that seen with usage of synthetic anabolic steroidal compounds but without adverse side-effects. The formulation composition of the invention comprises creatine, taurine, ribonucleic acid, and optimally, a carbohydrate (starch or a simple saccharide)component for enhancing cellular uptake. Other components such as alpha-ketoglutaric acid and salts thereof, and beta-hydroxy-beta-methyl butyric acid and salts thereof can be added for optimal results. The composition may be taken alone or in combination with a nutrient base, which typically includes protein source(s), carbohydrate(s), vitamin(s), and mineral(s) and other amino acids such as L-Glutamine and other natural L-form non-branched chain or branched chain amino acids. Actual studies in weight trained men show statistically significant increases in lean body mass yet with decreases in fat mass within 28 days.

Abstract: Compounds and a method useful for protection of tissue cells in a mammalian body from irreversible damages due to lactic acidosis caused by oxygen deficiency. The protection is achieved by administering a compound having a cell membrane permeability and/or ability to cross the blood brain barrier, said compound being able to provide a buffering action to prevent an increase in a hydrogen ion concentration over the physiologically acceptable levels or able to shift the intracellular pH to a more desired alkaline level.

Abstract: This invention relates to a method for modifying metabolism in a vertebrate animal which entails the administration of pantethine or cysteamine at a predetermined time daily. The method is useful in the treatment of hyperglycemia, glucose intolerance, insulin resistance, and hyperinsulinemia.

Abstract: Synergistic antimicrobial combinations comprising N-decyl-N-isononyl-N,N-dimethyl ammonium chloride and 2-(decylthio)ethanamine, or an acid salt therof, are disclosed. Methods for inhibiting microbial growth using these synergistic antimicrobial combinations are also disclosed.

Abstract: This invention is directed to a pharmacologically acceptable composition for inhibiting nitric oxide synthase in a mammal, which includes a mercapto derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting nitric oxide synthase, selectively inhibiting the inducible isoform of nitric oxide synthase, and treating various conditions where there is an advantage in inhibiting nitric oxide biosynthesis. The method includes the step of administering to a mammal a mercapto derivative in pure form or in a pharmaceutically acceptable carrier.

Abstract: The present invention relates to an anaesthetic veterinary pharmaceutical composition, comprising a general anaesthetic selected from phencyclidine derivatives such as ketamine or tiletamine, as well as 0.015 to 1.25 molar equivalents of selegiline, combined in a single pharmaceutical composition or presented separately.

Abstract: Topical application of cysteamine, cystamine, or phosphocysteamine to an appropriate bodily portion of a human is effective for the prevention of HIV infection.

Abstract: Ingestible compounds which are substantially tasteless and which have been found to be effective reducers or eliminators of undesirable tastes for eatables.

Abstract: Ingestible compounds which are substantially tasteless and which have been found to be effective reducers or eliminators of undesirable tastes for eatables.

Abstract: Quaternary amine-containing ether lipid analogs of the formulaR.sub.1 --X--R.sub.2 --N.sup.+ (R.sub.3) (R.sub.4) (R.sub.5) Z.sup.-are disclosed. R.sub.1 represents a hydrophobic group and R.sub.2 represents the backbone of the molecule, with the quaternary amine being linked directly to the backbone. Pharmaceutical compositions including these compounds and methods of combating tumors with these compounds are disclosed. Also disclosed is a method of combating viral infections with both these compounds and ET-18-OMe and its analogs.

Abstract: A non-toxic, environmentally safe and easily employable insecticide and insect repellant is achieved by providing an aqueous composition incorporating ethanolamine based compounds, either independently or in combination with the ethanolamine based compounds being selected from both simple compounds and conjugated compounds. In one preferred embodiment, a highly effective composition is attained for safe, effective, direct topical application to humans and animals by employing between about 10% and 70% by volume of the entire composition of the ethanolamine-based compound. In alternate preferred embodiments, the insecticide is formulated for application to plants, trees, crops, and other vegetation to provide a composition which effectively controls bothersome insects, while being completely safe and non-injurious to the plant, tree, or crop, as well as to the flowers or fruit thereof.

Abstract: The present invention relates to a method of treatment and a composition used to prevent the development of the adverse manifestation of tardive dyskinesia in individuals suffering from mental illness such as schizophrenia and undergoing treatment with neuroleptic or antipsychotic agents. The experimentally-based rationale for the present invention indicates that conventional neuroleptic drugs induce tardive dyskinesia because they evoke a glutamate afflux whose excitotoxic action is unopposed by other properties of these drugs, including dopamine receptor blockade. The present invention provides effective drug therapies for schizophrenia comprising conventional neuroleptics or antipsychotic drugs given in combination with taurine, a taurine precursor such as hypotaurine, taurine derivatives, or compounds similar in action to taurine, to render benign tardive dyskinesia as an adverse effect.

Abstract: Taurine analogues are used for scavenging active oxygen compounds and preventing and minimizing damage to the skin from ultraviolet rays. The taurine analogues have the following formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification.

Abstract: Macular degeneration is an age-related eye disease for which there is no known treatment to date that has been shown to be effective at treating or preventing the onset or progression of the disease. Current treatment of non-exudative (dry form) macular degeneration is limited to early diagnosis and careful followup, while symptomatic treatment of exudative (wet form) macular degeneration includes laser photocoagulation therapy, surgery, low dose radiation (teletherapy), and anti-oxidant or anti-inflammatory therapies. The present invention relates to a new method for treating or preventing the onset or progression of macular degeneration, comprising periodic administration of a glutathione (GSH) enhancing agent alone or in conjunction with at least one of an anti-oxidant or an anti-inflammatory therapy, and possibly in addition to one or more of the symptomatic treatments mentioned above.

Abstract: A method for inhibiting or relaxing skeletal muscle contractions which comprises contacting said skeletal muscle with a skeletal muscle relaxing amount, and a method for the treatment of disease states resulting from or exacerbated by undesirable contractions of skeletal muscle, which comprises administering a skeletal muscle relaxing amount to an individual in need thereof of a compound selected from the group consisting of nitroxyl ion (NO.sup.-), nitrosonium ion (NO.sup.+), nitric oxide and nitric oxide adducts or providers. This invention also is directed to stimulating the contraction of muscles in a mammal by administering an effective amount of a nitric oxide synthase inhibitor.

Abstract: A method and pharmaceutical for protecting against mutational damage in mammalian cells, irrespective of the nature of the mutagenic event or source of radiational or chemical insult or the like.

Abstract: Cysteamine, cystamine, and phosphocysteamine are effective agents for the treatment of HIV infections.

Abstract: A method of reducing the rate of mammalian hair growth includes topically applying a composition containing a sulfhydryl reactive compound to the skin.

Abstract: This invention relates to methods and compositions for obtaining synergistic anti-microbial (biocidal) activity using a combination of methylene(bisthiocyanate) and 2-bromo-2-nitropropane-1,3-diol. The methods and compositions of the invention are very effective in preventing microbial spoilage of latex carpet backing compounds and in paper and pulp preparation, particularly with respect to latex paper coatings. Compositions containing the active ingredients in ratios of from 0.001 parts methylene(bisthiocyanate) to 1 part 2-bromo-2-nitro-propane-1,3-diol to 10 parts methylene(bisthiocyanate) to 1 part 2-bromo-2-nitro-propane-1,3-diol.

Abstract: Compounds and a method useful for protection of tissue cells in a mammalian body from irreversible damages due to lactic acidosis caused by oxygen deficiency. The protection is achieved by administering a compound having a cell membrane permeability and/or ability to cross the blood brain barrier and being able to provide a buffering action to prevent an increase in a hydrogen ion concentration over the physiologically acceptable levels.

Abstract: The present invention relates to an anti-fouling coating composition that comprises a marine biocide and a binder which is a hydrolyzable film-forming seawater-erodible polymer. The polymer contains sulphonic acid groups in quaternary ammonium salt form.

Abstract: A microbial inhibiting composition and method is disclosed. The composition comprises an amount, effective for the intended purpose of decylthioethanamine hydrochloride and 2-(2-bromo-2-nitroethenyl) furan. The method comprises administering an amount of this combined treatment to the particular water containing system for which treatment is desired.

Abstract: Zwitterionic compounds selected from:taurine (2-aminoethanesulphonic acid),2(N-morpholino)ethanesulphonic acid (MES),N-(2-acetamido)iminodiacetic acid (ADA),piperazine-N,N'bis(2-ethanesulphonic acid (PIPES),N-(2-acetamido)-2-aminoethanesulphonic acid (ACES),N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES),3-(N-morpholino)propanesulphonic (MOPS),N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES),N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES),N-2-hydroxyethylpiperazine-N'3-propanesulphonic acid (H)EPPS),2-(cyclohexylamino)ethanesulphonic acid (CHES) or 3-(cyclohexylamino)propanesulphonic acid (CAPS),and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter alia to enhanced leukotriene inactivation.

Abstract: Irrigating solutions with thiol or disulfide containing compounds in physiologically acceptable salt solutions are described. The irrigating solutions are useful during surgery, particularly ophthalmic, neural, cardiovascular or otic surgery, to stabilize the affected tissue. Methods for their preparation and use are described.

Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.

Abstract: The present invention relates to novel compounds represented by the formula: ##STR1## wherein R is an alkyl group having from about 8 to about 18 carbon atoms, and mixtures thereof, n has a value from 1 to 6, R.sub.1 is selected from the group consisting of an alkyl group having from 1 to about 12 carbon atoms, H, or ##STR2## wherein the sum of n-m=3 to 12, Z.dbd.H or SO.sub.3 M and M.dbd.NH.sub.4, Na, or K. These compounds possess antimicrobial activity and are useful as cleaning agents and preservatives, particularly in water-base functional fluids and surface coating compositions.

Abstract: The present invention is directed to a combination of two types of biocidal materials that give rise to synergistic effects against microorganisms in aqueous systems such that the extent to which the microorganisms are killed exceeds that which one would expect from using the sum of the individual components of the composition. More specifically, this invention is directed to a combination comprising 2-(decylthio)ethaneamine and 1,2-dibromo-2,4-dicyanobutane in an amount effective to inhibit microbial growth. This combination has proven to be particularly effective in inhibiting the growth of Enterobacter aerogenes ATCC 13048 in aqueous systems.

Abstract: The present invention is directed to an antimicrobial composition and a method of using said composition, comprising an antimicrobially effective amount of DTEA and an amount of 1-butanol, cyclohexanol, hexyl alcohol, isobutanol, ethylene glycol phenyl ether, propylene glycol phenyl ether, or a mixture thereof effective to result in the antimicrobial composition having a freezing point of less than 0.degree. C. at atmospheric pressure.